Dr. Adi Hoess Joins ALKemist Bio Board; Former CEO of Affimed N.V.

ALKemist Bio Strengthens Leadership with Dr. Adi Hoess Appointment

ALKemist Bio, a biotechnology company dedicated to advancing treatments for ALK-positive cancers, announces the appointment of Dr. Adi Hoess as an independent director on its Board. Dr. Hoess, known for his extensive 30-year career in the biopharmaceutical sector, previously served as the CEO of Affimed N.V., a company renowned for its innovative immuno-oncology therapies. His strategic insights and leadership in developing cellular therapies are expected to align seamlessly with ALKemist Bio’s mission to target the Anaplastic Lymphoma Kinase (ALK) oncogene, which is pivotal in the pathology of aggressive and recurrent cancers.

Under Dr. Hoess’s guidance, ALKemist Bio aims to enhance its preclinical evaluations and prepare for clinical development focusing on T cell-based therapies specifically designed for ALK-positive tumors. These tumors pose significant challenges, particularly for patients who have shown limited response to current ALK inhibition treatments. The appointment comes at a crucial time as the company is on the cusp of advancing its pipeline, and Dr. Hoess’s expertise is anticipated to play a critical role in navigating the complexities of cellular therapy development.

Executive Chairman Pietro Puglisi highlights the importance of Dr. Hoess’s experience, asserting that his knowledge in biotech innovation will be vital for ALKemist Bio’s growth trajectory. Dr. Hoess expresses enthusiasm for contributing to ALKemist's mission, emphasizing the potential of T cell-based therapies to provide durable responses for patients facing ALK-positive tumors, which often relapse despite existing treatment protocols. This appointment reflects ALKemist Bio’s commitment to pioneering transformative therapies for patients in need.

In addition to this leadership change, ALKemist Bio has marked significant milestones over the past year, including securing €6.9 million in funding through an investment round led by Claris Ventures. This financial backing positions the company favorably as it continues to progress in the development of novel cancer therapies. The strategic direction set by the Board, now bolstered by Dr. Hoess, signals ALKemist Bio's ambition to make substantial contributions to the oncology landscape in the near future.